South African Dyslipidaemia Guideline Consensus Statement

The European Society of Cardiology together with the European Atherosclerosis Society published updated dyslipidaemia guidelines in 2011. SA Heart and the Lipid and Atherosclerosis Society of Southern Africa officially adopt these guidelines. This statement adapts aspects of the guidelines to the South African situation. Using the updated Framingham risk charts, interventional strategies are based according to the cardiovascular risk score and low-density lipoprotein cholesterol (LDL-C) levels. The Framingham risk score refers to the 10-year risk of any cardiovascular event, and includes four categories of risk. Treatment targets are those of the European guidelines. The LDL-C goal is 1.8 mmol/l for the very high-risk group (>30%), 2.5 mmol/l for the high-risk group (15–30%), and 3 mmol/l for those below 15% risk. Intensive management of dyslipidaemia in South Africa will significantly reduce the cardiovascular disease health burden.

[1]  E. Colman,et al.  Weighing the benefits of high-dose simvastatin against the risk of myopathy. , 2011, The New England journal of medicine.

[2]  M. Taskinen,et al.  ESC/EAS Guidelines for the management of dyslipidaemias: the Task Force for the management of dyslipidaemias of the European Society of Cardiology (ESC) and the European Atherosclerosis Society (EAS). , 2011, Atherosclerosis.

[3]  M. Landray,et al.  The effects of lowering LDL cholesterol with simvastatin plus ezetimibe in patients with chronic kidney disease (Study of Heart and Renal Protection): a randomised placebo-controlled trial , 2011, The Lancet.

[4]  Rowena J Dolor,et al.  Effectiveness-based guidelines for the prevention of cardiovascular disease in women--2011 update: a guideline from the American Heart Association. , 2011, Journal of the American College of Cardiology.

[5]  R. Eckel Approach to the patient who is intolerant of statin therapy. , 2010, The Journal of clinical endocrinology and metabolism.

[6]  Shu-Hua Tai,et al.  A systematic review and meta‐analysis on the therapeutic equivalence of statins , 2010, Journal of clinical pharmacy and therapeutics.

[7]  S. Basili,et al.  Nutrition, Supplements, and Vitamins in Platelet Function and Bleeding , 2010, Circulation.

[8]  Yasuo Ohashi,et al.  Statins and risk of incident diabetes: a collaborative meta-analysis of randomised statin trials , 2010, The Lancet.

[9]  S. Grundy,et al.  Harmonizing the metabolic syndrome: a joint interim statement of the International Diabetes Federation Task Force on Epidemiology and Prevention; National Heart, Lung, and Blood Institute; American Heart Association; World Heart Federation; International Atherosclerosis Society; and International As , 2009, Circulation.

[10]  Paul M. Ridker,et al.  Statin Therapy and Risk of Developing Type 2 Diabetes: A Meta-Analysis , 2009, Diabetes Care.

[11]  J. Rood,et al.  Comparison of weight-loss diets with different compositions of fat, protein, and carbohydrates. , 2009, The New England journal of medicine.

[12]  A. Stalenhoef,et al.  Effects of ubiquinone (coenzyme Q10) on myopathy in statin users , 2008, Current opinion in lipidology.

[13]  M. Pencina,et al.  General Cardiovascular Risk Profile for Use in Primary Care: The Framingham Heart Study , 2008, Circulation.

[14]  P. Thompson,et al.  The role of coenzyme Q10 in statin-associated myopathy: a systematic review. , 2007, Journal of the American College of Cardiology.

[15]  S. Yusuf,et al.  Risk Factors Associated With Myocardial Infarction in Africa: The INTERHEART Africa Study , 2005, Circulation.

[16]  S. Yusuf,et al.  Effect of potentially modifiable risk factors associated with myocardial infarction in 52 countries (the INTERHEART study): case-control study , 2004, The Lancet.

[17]  Shah Ebrahim,et al.  JOINT ESC GUIDELINES 2016 European Guidelines on cardiovascular disease prevention in clinical practice – Web Addenda , 2016 .

[18]  P. Toth Risk of Incident Diabetes With Intensive-Dose Compared With Moderate-Dose Statin Therapy: A Meta-analysis , 2012 .

[19]  N. Unwin,et al.  Expert Panel on Detection, Evaluation, and Treatment of High Blood Cholesterol in Adults (Adult Treatment Panel III) Detection, Evaluation, and Treatment of High Blood Cholesterol Education Program (NCEP) Expert Panel on Executive Summary of the Third Report of the National , 2009 .

[20]  K. Steyn THE HEART AND STROKE FOUNDATION SOUTH AFRICA HEART DISEASE IN SOUTH AFRICA MEDIA DATA DOCUMENT , 2007 .

[21]  D. Jacobs,et al.  Confidential. Do Not Distribute. Pre-embargo Material. Dietary Supplements and Mortality Rate in Older Women , 2022 .